In a patient with epistaxis who is taking aspirin (acetylsalicylic acid) for secondary cardiovascular prevention, should the aspirin be held until bleeding is controlled?

Do Not Hold Aspirin for Epistaxis

In patients with nosebleeds taking aspirin for cardiovascular prevention, you should NOT routinely stop the aspirin—instead, use first-line local control measures (nasal compression, vasoconstrictors, cautery, or packing) before considering withdrawal of antiplatelet therapy. 1

Primary Management Strategy

The 2020 American Academy of Otolaryngology clinical practice guideline explicitly states that in the absence of life-threatening bleeding, clinicians should initiate first-line treatments prior to withdrawal of anticoagulation/antiplatelet medications 1. This recommendation prioritizes avoiding the thrombotic risks associated with aspirin withdrawal over the bleeding risks, which can typically be controlled with local measures.

Why Continuing Aspirin is Critical

• Aspirin withdrawal syndrome is real and dangerous: Stopping aspirin creates a platelet rebound phenomenon and prothrombotic state that significantly increases the risk of major adverse cardiovascular events, particularly in the perioperative period 2
• Most patients taking aspirin are on it for secondary cardiovascular prevention (meaning they've already had a cardiac event), making the thrombotic risk of stopping aspirin substantially higher than the bleeding risk of continuing it 2
• The thrombotic risk is amplified during acute medical stress like an epistaxis episode requiring intervention

First-Line Treatment Approach

Before even considering aspirin withdrawal, implement these local control measures:

1. Firm sustained nasal compression to the soft part of the nose for at least 10-15 minutes 1
2. Topical vasoconstrictors (oxymetazoline spray or cotton pledgets) 1
3. Nasal cautery after anesthetizing the bleeding site (silver nitrate or bipolar cautery) 1
4. Nasal packing with resorbable materials (specifically recommended for patients on antiplatelet agents) 1
5. Topical tranexamic acid (TXA)—shown to be highly effective in aspirin/clopidogrel patients, with faster bleeding control (6.7 vs 11.5 minutes) and lower rebleeding rates (6% vs 20%) compared to standard packing 3

Evidence Supporting Local Control First

The guideline development group explicitly valued avoiding thrombotic events over prolonging time to bleeding resolution 1. They acknowledged that clinicians should be willing to accept a slightly longer time to achieve hemostasis rather than expose patients to the substantially increased cardiovascular risk of aspirin withdrawal.

When to Consider Holding Aspirin

Only consider stopping aspirin if:

• Life-threatening bleeding that cannot be controlled with aggressive local measures 1
• Hemodynamic instability from blood loss requiring emergent intervention 1
• The bleeding persists despite multiple attempts at cautery, packing, and potentially surgical arterial ligation or endovascular embolization 1

Even in these extreme cases, the decision should involve consultation with the patient's cardiologist to weigh cardiovascular risk.

Critical Caveats

Aspirin significantly increases epistaxis recurrence risk: Long-term data shows aspirin intake is an independent risk factor for requiring surgical intervention for recurrent epistaxis 4, and patients on aspirin have more frequent recurrences and changes in bleeding location 5. However, this recurrence risk does NOT justify routine discontinuation—it justifies better local control and patient education.

Questionable indications: Up to 40% of patients taking prophylactic aspirin may have questionable indications for the medication 5. This is the time to review the appropriateness of aspirin therapy with the prescribing physician, not to unilaterally stop it during an acute bleed.

Resorbable packing is preferred: The guideline specifically recommends using resorbable packing materials for patients on antiplatelet medications 1, as this reduces the need for follow-up removal and associated rebleeding risk.

Practical Algorithm

1. Control bleeding locally first (compression → vasoconstrictors → cautery → packing/TXA)
2. Continue aspirin unless life-threatening bleeding
3. Consult cardiology if considering aspirin withdrawal
4. Review appropriateness of aspirin indication during hospitalization
5. Use resorbable packing if packing is required
6. Educate patient on preventive measures (nasal humidification, saline sprays, avoiding nose-picking)

The evidence is clear: local control measures are effective even in antiplatelet patients, and the cardiovascular risks of stopping aspirin far outweigh the bleeding risks in the vast majority of epistaxis cases 1, 2.